The role of high-dose chemotherapy in the treatment of multiple myeloma: A controversy

Annals of Oncology

Volumn 11, Issue SUPPL. 1, 2000, Pages

  Kyle, R A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autologous and allogeneic transplantation; High dose; Multiple myeloma; Therapy

Indexed keywords

ALPHA2 INTERFERON; CYCLOPHOSPHAMIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PREDNISONE;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0033996881     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/11.suppl_1.S55     Document Type: Conference Paper

References (19)

1. Kyle RA. Benign monoclonal gammopathy after 20 to 35 years of follow-up. Mayo Clin Proc 1993; 68: 26.
2. Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med 1980; 302: 1347.
3. Kyle RA, Gertz MA. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45.
4. Greipp PR, Witzig TE, Gonchoroff NJ et al. Immunofluorescence labeling indices in myeloma and related monoclonal gammopathies. Mayo Clin Proc 1987: 62: 969.
5. Witzig TE, Kyle RA, O'Fallon WM, Greipp PR. Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. Br J Haematol 1994: 87: 266.
6. Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832.
7. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autolgous peripheral blood stem-cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized trial. Blood 1998; 92: 3131.
8. Vesole DH, Tricot G, Jagannath S et al. Autotransplanls in multiple myeloma: What have we learned? Blood 1996; 88: 838.
9. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999; 93: 55-65.
10. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med 1996; 335: 91.
11. Bladé J, San Miguel JE, Fontanillas M et al. Survival of multiple myeloma patients who arc potential candidates for early high-dose therapy intensification/autotransplantation and who were conventionally treated. J Clin Oncol 1996; 14: 2167.
12. Attal M, Payen C, Facon T et al. Single versus double transplant in myeloma: A randomized trial of the 'Intergroupe Français du Myélome' (IFM). Blood 1997; 90: 418a (Abstr).
13. Goldschmidt H. Cremer FW. Hegenbart U et al. Comparison of 3 high-dose regimens with autologous peripheral blood stem-cell transplantation (TPX) for multiple myeloma (MM): A single center experience in 230 patients (PTS). Am Soc Clin Oncol 19999; 18: 5a.
14. Vesico R, Stewart A, Ballester O et al. Myeloma cell tumor reduction in PBPC autografts following CD34 selection: The results of a phase III trial using the CEPRATE device. Blood 1997; 90: 421a.
15. Tricot G, Gazitt Y. Leemhuis T et al. Collection, tumor contamination and engraftment kinetics of highly purified hematopoietic progenitor cells to support high-dose therapy in multiple myeloma. Blood 1998; 91: 4489.
16. Gharton G, Tura S, Svensson H et al. Allogeneic bone marrow transplantation in multiple myeloma an update of the EBMT Registry. Sixth International Workshop on Multiple Myeloma. Syllabus, Boston, MA: Syllabus, 14 18 June 1997.
17. Giralt S, Weber D, Cohen A et al. Non-myeloablative conditioning with fludarabine (F)/melphalan (M) for patients with multiple myeloma (MM). Am Soc Clin Oncol 1999; 18: 6a.
18. Tricot G, Vesole DH, Jagannath S et al. Graft-versus-myeloma effect: Proof of principle. Blood 1996; 87: 1996.
19. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood 1997: 90: 4206.